Biomarkers for screening, predicting, and monitoring prostate disease
Gene expression data are analyzed using learning machines such as support vector machines (SVM) and ridge regression classifiers to rank genes according to their ability to separate prostate cancer from BPH (benign prostatic hyperplasia) and to distinguish cancer volume. Other tests identify biomarker candidates for distinguishing between tumor (Grade 3 and Grade 4 (G3/4)) and normal tissue.
1 . A biomarker for screening, predicting, and monitoring prostate cancer volume comprising any combination of the genes identified by Unigene ID numbers of the table in FIG. 19 .
2 . A biomarker for screening, predicting, and monitoring prostate cancer comprising two or more genes selected from the group consisting of cDNA DKFZp564A072, GSTP1, HPN, TACSTD1, ANGPT1, PTGDS, RRAS, Ncoa4, Pak6-ESTs, Tmf1-ESTs (ARA160), 2010301M18Rik (Cyp2c19), Acpp, Adh1, Akr1b3 (aldose reductase), Aldh1a1 (ALDH1), Dhcr24 (seladin-1), Folh1 (PSMA), Gpx5, Klk4, Morf-pending, Myst1, Ngfa, Ppap2a, Ppap2b, Srd5a2, Tgm4 (hTGP), Tmprss2, Anxa7, Apoe, Cdhl, Enh-pending (Lim), Gstpl, Hpn (Hepsin), Olfr78 (PSGR), Pov1, Psca, Pten, Ptov1, Sparcl1 (HEVIN), Steap, Tnfrsf6 (FAS), C20orf1-Rik (FLS353), Fat, Fbxl11, Igf1, Igfbp5, Kcnmb1, Mta1, Mybl2, Oxr1 (C7), Ppap2b, Rab5a, Rap1a, and Sfrp4.
3 . A method for distinguishing between benign prostate hyperplasia (BPH) and tumor in prostate tissue comprising screening for gene expression of ten or fewer genes selected from the group of genes identified by Unigene ID numbers of the table in FIG. 10 , FIG. 24 , FIG. 25 and Table 38.
4 . The method of claim 3 , wherein the gene expression is tested in serum.
5 . The method of claim 3 , wherein the gene expression is tested in biopsied prostate tissue.
6 . The method of claim 3 , wherein the gene expression is tested in semen.
7 . A method for distinguishing between benign prostate hyperplasia (BPH) and tumor in prostate tissue comprising screening for gene expression of more than ten genes selected from the group of genes identified by Unigene ID numbers of FIG. 10 , FIG. 24 , FIG. 25 and Table 38.
8 . The method of claim 7 , wherein the gene expression is tested in serum.
9 . The method of claim 7 , wherein the gene expression is tested in biopsied prostate tissue.
10 . The method of claim 7 , wherein the gene expression is tested in semen.
11 . A method for distinguishing between G3 and G4 prostate cancer tumors and non G3 and G4 tissue comprising screening for gene expression of 100 or fewer genes selected from the group of genes identified by Unigene ID numbers of the tables of FIG. 11 , FIG. 20 , FIG. 23 , FIG. 26 , FIG. 27 or Table 38.
12 . The method of claim 11 , wherein the gene expression is tested in serum.
13 . The method of claim 11 , wherein the gene expression is tested in biopsied prostate tissue.
14 . The method of claim 11 , wherein the gene expression is tested in semen.
15 . A method for distinguishing between G3 and G4 prostate cancer tumors and non G3 and G4 tissue comprising screening for gene expression of 100 or more genes selected from the group of genes identified by Unigene ID numbers of the tables in FIG. 1 , FIG. 20 , FIG. 23 , FIG. 26 , FIG. 27 or Appendix 2.
16 . The method of claim 15 , wherein the gene expression is tested in serum.
17 . The method of claim 15 , wherein the gene expression is tested in biopsied prostate tissue.
18 . The method of claim 15 , wherein the gene expression is tested in semen.
19 . A method for distinguishing between G4 prostate cancer tumors and non G4 tissue comprising screening for gene expression of 100 or fewer genes selected from the group of genes identified by Unigene ID numbers of the table of FIG. 12 .
20 . The method of claim 19 , wherein the gene expression is tested in serum.
21 . The method of claim 19 , wherein the gene expression is tested in biopsied prostate tissue.
22 . The method of claim 19 , wherein the gene expression is tested in semen.